Cardiology

Dr Sahil Parikh and other experts discuss engagement of cardiologists in patients diagnosed with polyvascular disease and challenges in screening patients.

Steve R. Ommen, MD, leads a review of common mutations seen in hypertrophic cardiomyopathy and the role of biomarkers and genetic testing in HCM.

Martin S. Maron, MD, discusses the incidence and prevalence of hypertrophic cardiomyopathy and age of disease expression.

Data show 7 risk factors, many potentially modifiable, accounted for 85% of the risk of first AMI in young women and men.

Investigators use data from the CDC WONDER database to assess contemporary trends in disease-specific cardiovascular causes of mortality among cancer patients in the US from 1999 to 2019.

The participants included more than 2,000 pregnant individuals at higher risk of preeclampsia.

A 3-month trial found reducing sedentary time by just an hour per day was enough to produce statistically significant changes in biomarkers for cardiovascular risk among patients with metabolic syndrome.

An analysis of data from more than 2000 matched pairs suggests the impact of multiple risk factors, including diabetes, depression, and hypertension, on the risk of acute myocardial infarction were greater among young women than their male counterparts.

Study investigators used data from midlife checkpoints and late life checkpoints for participants without heart failure.

In this episode of Don't Miss a Beat, hosts Drs. Greene and Vaduganathan break down the new ACC/AHA/HFSA heart failure guidelines debuted at ACC.22 and compare the recommendations against those made in the European Society of Cardiology's 2021 heart failure guidelines.

An analysis of data from the Cleveland Clinic Echocardiography database provides an overview of the association between the use of calcium supplements with increased risk of mortality and worsening stenosis among older patients with aortic stenosis.

New data suggests the number of prescriptions for SGLT2 inhibitors in the US has doubled since 2015 with prescriptions for GLP-1 receptor agonists tripling during the same time period.

Martin Maron, MD, medical director of the Hypertrophic Cardiomyopathy Center at Lahey Hospital and Medical Center, participates in a Q&A related to the approval of mavacamten for symptomatic obstructive hypertrophic cardiomyopathy.

Dr Amy Pollak and other experts discuss their recommendations for screening for CAD and PAD in asymptomatic patients.

Drs Marc Bonaca and Manesh Patel provide an overview of Polyvascular Disease and prevalence of coronary artery disease and peripheral artery disease.

Bristol Myers Squibb announced the FDA's approval of mavacamten for symptomatic obstructive hypertrophic cardiomyopathy in a press release on April 28.

A systematic review and meta-analysis suggest available evidence demonstrates the addition of coronary artery calcium scores provides incremental gain to traditional cardiovascular risk assessments but this benefit may not outweigh the risks and costs associated with CACS.

The decision to initiate low-dose aspirin use for CVD prevention in adults aged 40 to 59 years with a 10% or greater 10-year CVD risk should be individualized.

Published in JAMA on April 26, the latest recommendation statement from the USPSTF gives a grade C recommendation for use of low-dose aspirin for primary prevention of cardiovascular disease in adults aged 40-59 years who have a 10% or greater 10-year cardiovascular disease risk, concluding it could provide a small net benefit in these patients.

An analysis of the DAPA-HF trial provides insight into the occurrence of eGFR dips in the first 14 days following initiation of therapy with an SGLT2 inhibitor and their association with long-term outcomes.

An analysis of the REWIND trial suggests baseline cognitive impairment was associated with a 1.6 times greater risk of major adverse cardiovascular events among patients with type 2 diabetes.

Data show 15-mg edoxaban dose was superior to placebo in preventing stroke or systemic embolism in all 3 age strata studied, with higher incidence of major bleeding.

The 2022 State of the Air report from the American Lung Association highlights growing disparities in coastal-based ozone and particle pollution, amid wildfires and shifts in regulatory policies.

Analysis of the REWIND trial indicates cognitive impairment among patients with diabetes was associated with a 1.6 times greater risk of major adverse cardiovascular events and a 1.8 times greater risk of stroke or mortality.

Data from an analysis of more than 23,000,000 in Europe provides a comprehensive overview of the risk of myocarditis and pericarditis following COVID-19 vaccination, according to age, sex, and vaccine type.